Immunization with DNA coding for gp100 results in CD4+ T-cell independent antitumor immunity Journal Article


Authors: Hawkins, W. G.; Gold, J. S.; Dyall, R.; Wolchok, J. D.; Hoos, A.; Bowne, W. B.; Srinivasan, R.; Houghton, A. N.; Lewis, J. J.
Article Title: Immunization with DNA coding for gp100 results in CD4+ T-cell independent antitumor immunity
Abstract: Background. Xenogeneic DNA immunization can exploit small differences in expressed protein sequence resulting in immune recognition of self-molecules. We hypothesized that immunizing mice with xenogeneic DNA coding for the human melanosomal membrane glycoprotein gp 100 would overcome immune ignorance or tolerance and result in tumor immunity. We also investigated the immunologic mechanisms of the antitumor immunity. Methods. C57BL/6 mice were immunized with DNA coding for human gp 100, mouse gp 100, or control vector by gene gun. After immunization, mice were challenged with a syngeneic melanoma expressing gp 100, and tumor growth was analyzed. Mice deficient in major histocompatibility complex class I or class II molecules were similarly studied to assess the immunologic mechanism of the tumor protection. Results. There was significant tumor protection after vaccination with xenogeneic human gp 100 DNA. Class I, but not class II, major histocompatibility complex molecules were required for tumor immunity. In addition, mice immunized with human gp 100 demonstrated autoimmunity manifested as coat color depigmentation. Conclusions. Immunization with xenogeneic DNA coding for the melanosomal glycoprotein gp 100 results in tumor protection and autoimmune depigmentation. These results show that xenogeneic DNA vaccines can lead to cancer immunity without CD4+ T-cell help with potential implications for rational vaccine design.
Keywords: controlled study; nonhuman; t lymphocyte; mouse; animals; mice; cell division; glycoprotein gp 100; spleen; lung neoplasms; neoplasm proteins; animal experiment; animal model; mice, inbred c57bl; genetic vectors; immunological tolerance; immune response; regulatory mechanism; amino acid sequence; sequence alignment; membrane glycoproteins; major histocompatibility antigen class 2; antigen recognition; cd4-positive t-lymphocytes; t-lymphocytes, cytotoxic; melanoma, experimental; tumor immunity; autoimmunity; cytotoxicity, immunologic; dna vaccine; tumor growth; major histocompatibility complex; vaccines, dna; antibody formation; major histocompatibility antigen class 1; immunization; granulocyte macrophage colony-stimulating factors, recombinant; humans; priority journal; article
Journal Title: Surgery
Volume: 128
Issue: 2
ISSN: 0039-6060
Publisher: Elsevier Inc.  
Date Published: 2000-08-01
Start Page: 273
End Page: 280
Language: English
DOI: 10.1067/msy.2000.107421
PUBMED: 10923004
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Jonathan J Lewis
    109 Lewis
  3. Rubendra Dyall
    33 Dyall
  4. William G Hawkins
    18 Hawkins
  5. Axel Hoos
    28 Hoos
  6. Jason Gold
    21 Gold
  7. Wilbur B Bowne
    20 Bowne
  8. Alan N Houghton
    364 Houghton